2024-10-15 - Analysis Report
## Pfizer Inc. (PFE) Stock Analysis Report

**1. Performance and Relative Strength**

Pfizer Inc. (PFE) is a global pharmaceutical company specializing in the research, development, and manufacturing of medicines and vaccines.  

- **Cumulative Return:** -11.77%
- **S&P 500 (VOO) Cumulative Return:** 135.82%
- **Divergence:** -147.59% (Relative Divergence: 0.0%)

Pfizer has significantly underperformed the S&P 500 over the period analyzed.  The divergence indicates PFE is significantly lagging behind the market, as its cumulative return is 147.59% lower than the S&P 500. 

**2. Recent Price Movement**

- **Closing Price:** $29.16
- **5-day Moving Average:** $29.42
- **20-day Moving Average:** $29.24
- **60-day Moving Average:** $29.27

The current price is slightly below the recent moving averages, indicating a potential for further decline. 

**3. Technical Indicators**

- **RSI:** 48.33
- **PPO:** 0.15
- **Delta_Previous_Relative_Divergence:** -1.74
- **Expected Return:** 0.0%

The RSI suggests that the stock is currently neutral. The PPO indicates a slight upward trend. The negative Delta_Previous_Relative_Divergence suggests a recent short-term downward movement. The expected return is 0.0%, implying a potential for stagnation or even further decline.

**4. Recent Earnings and Outlook**

| Date       | EPS | Expected EPS |
|------------|-----|--------------|
| 2024-07-30 | 0.6 | 0.458       |
| 2024-05-01 | 0.82| 0.516       |
| 2024-01-30 | 0.1 | -0.19       |
| 2023-10-31 | -0.17| -0.32       |
| 2023-08-01 | 0.67| 0.56        |

Pfizer's recent earnings have been inconsistent. While the company has exceeded expectations in recent quarters, it also experienced significant losses in the previous year. This suggests that PFE's future performance might be volatile.

**5. News and Recent Events**

- **Recent Market Outlook:** Pfizer's stock has been facing pressure due to concerns about declining COVID-19 vaccine demand and the overall macroeconomic uncertainty.
- **Analyst Opinions:**  Analysts are generally bullish on Pfizer's long-term prospects, citing its strong pipeline of innovative drugs and its dominance in the vaccine market. However, they also acknowledge the challenges posed by the current market environment.
- **Performance Highlights:** Pfizer's recent focus on expanding its product portfolio beyond COVID-19 has been well-received by investors. 

**6. Summary**

Pfizer is a well-established pharmaceutical company with a strong track record. However, the stock has been underperforming the market due to several factors, including concerns about declining COVID-19 vaccine demand and macroeconomic uncertainty. While the company's long-term prospects are promising, investors should be cautious due to the current volatile market environment. The short-term technical indicators suggest a potential for further decline. 

**7. Recommendations**

- **Long-Term:** Pfizer's long-term fundamentals are strong, making it a potential investment for long-term investors.
- **Short-Term:** Investors should be cautious in the short term due to the recent underperformance and the negative short-term indicators. 

**Disclaimer:** This analysis is for informational purposes only and should not be considered investment advice. Always consult with a qualified financial advisor before making any investment decisions.